Corrigendum to “Linezolid for Treating Tuberculosis: A Delicate Balancing Act” [EBioMedicine 2 (11) (November 2015) 1568–1569]
ثبت نشده
چکیده
In the fourth paragraph, the last sentence " In a meta-analysis failure rates were almost fourfold higher with the 300 mg than the 600 mg daily dose (Zhang et al., 2015) " is an incorrect statement. The authors would like to withdraw this statement and apologize for the error.
منابع مشابه
Linezolid for Treating Tuberculosis: A Delicate Balancing Act
There is an urgent need for better regimens to treat drug-resistant tuberculosis (DR-TB). Treatment for multi-drug resistant tuberculosis (MDR-TB, defined as resistance to both isoniazid and rifampicin) has a success rate of only 64% (Falzon et al., 2013), is prolonged for up to 24 months, and is poorly tolerated. Treatment success for extensively drug-resistant tuberculosis (XDR-TB, defined as...
متن کاملLinezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Long-term linezolid use is limited by mitochondrial toxicity-associated adverse events (AEs). Within a prospective, randomized controlled trial of linezolid to treat chronic extensively drug-resistant tuberculosis, we serially monitored the translational competence of mitochondria isolated from peripheral blood of participants by determining the cytochrome c oxidase/citrate synthase activity ra...
متن کاملEfficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
Linezolid may be effective in treating multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. We conducted a prospective, multicentre, randomised study to further evaluate the efficacy, safety and tolerability of linezolid in patients with extensively drug-resistant tuberculosis in China. 65 patients who had culture-positive sputum for extensively drug-resistant tuberculo...
متن کاملCorrigendum to “Syk and ye shall find” [EBioMedicine 2 (11) (2015) 190-1591]
The authors wish to point out that in the original Commentary (DOI: S2352-3964(15)00180-2), the spelling of Dr. Geahlen's name is incorrect throughout, and that reference to the original Research Article by Ghosh and Geahlen is missing. In the first line of paragraph 4, the relevant sentence should read: “Enter the article by Ghosh and Geahlen (Ghosh and Geahlen, 2015, DOI: S2352-3964(15)30168-...
متن کاملErratum to “Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis” [EBioMedicine 2 (8), August 2015, 868–873]
Onpage 867, third paragraph of the Introduction Section, the followShould read: ing sentence, “In efforts to block pro-inflammatory responses, we recently showed that tofacitinib, a Janus kinase (JAK) inhibitor that was FDA-approved in 2012 for treating rheumatoid arthritis and ulcerative colitis (Traynor, 2012; Sandborn et al., 2012), blocked immune containment and promoted bacterial replicati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 3 شماره
صفحات -
تاریخ انتشار 2016